Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/55—IL-2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
  • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2013—IL-2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
  • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
  • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

• Polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Ra chain interleukin-2 (IL-2) interleukin-2 receptor alpha (IL-2Ra) hold great promise as anti-cancer agents.
• IL-2Ra chain interleukin-2 (IL-2) interleukin-2 receptor alpha (IL-2Ra) hold great promise as anti-cancer agents.
• These polypeptide s retain full ability to signal through the intermediate-affinity IL-2R complex that is expressed on memory CD8+ T cells and Natural Killer (NK) cells, but are sterically prevented from binding to the high-affinity IL-2R complex that is preferentially expressed on CD4+ FOXP3+ regulatory T cells (CD4+ Tregs) and endothelial cells.
• the polypeptides selectively activate CD8+ T cells and NK cells, thereby promoting tumor cell killing.
• the inability to activate the high-affinity IL-2R on endothelial cells may also reduce the risk of toxicity due to capillary leak syndrome, a known risk of IL-2 therapies.
• the aforementioned polypeptides When used for the treatment of human subjects, the aforementioned polypeptides must be stored prior to use and transported to the point of administration. Reproducibly attaining a desired level of polypeptide in a subject requires that the polypeptide be stored in a formulation that maintains the bioactivity of the polypeptide. Accordingly, there is a need in the art for stable compositions of polypeptides. Preferably, such compositions will exhibit a long shelf-life, and be stable when stored and transported.
• compositions comprising polypeptides comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Ra chain, and methods of making and using such compositions. These compositions are specifically formulated to improve the stability and shelf-life of the polypeptides contained therein.
• the disclosure provides a composition comprising: a) about 1 mg to about 50 mg of a polypeptide comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Ra chain; b) sucrose; c) mannitol; c) citrate buffer; and d) an emulsifier.
• the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1. In certain embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. In certain embodiments, the polypeptide consists of the amino acid sequence of SEQ ID NO: 1.
• the composition comprises about 1 mg to about 15 mg of the polypeptide. In certain embodiments, the composition comprises about 1 mg of the polypeptide. In certain embodiments, the composition comprises about 5 mg of the polypeptide. In certain embodiments, the composition comprises about 15 mg of the polypeptide. In certain embodiments, the composition comprises about 20 mg of the polypeptide. In certain embodiments, the composition comprises about 30 mg of the polypeptide.
• the composition comprises about 60 mg to about 72 mg sucrose. In certain embodiments, the composition comprises about 66 mg sucrose.
• the composition comprises about 60 mg to about 72 mg mannitol. In certain embodiments, the composition comprises about 66 mg mannitol.
• the composition comprises about 4.0 mg to about 6.0 mg citrate anion. In certain embodiments, the composition comprises about 5.0 mg citrate anion.
• the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of between about 1:10 to about 1:2 (i.e., about 1:10, about 1:9, about 1:8, about 1:7, about 1:6, about 1:5, about 1:4, about 1:3, and about 1:2).
• the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid: sodium citrate tribasic dihydrate of about 1:9. In certain embodiments, the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid: sodium citrate tribasic dihydrate of about 1:2.
• the emulsifier comprises polysorbate 20. In certain embodiments, the composition comprises about 0.20 mg to about 0.24 mg polysorbate 20. In certain embodiments, the composition comprises about 0.22 mg polysorbate 20.
• the composition comprises about 0.10 mg to about 0.12 mg polysorbate 20. In certain embodiments, the composition comprises about 0.11 mg polysorbate 20.
• the composition is a lyophilized cake.
• dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 5.5 to about 6.5. In certain embodiments, dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 6.1. [018] In certain embodiments, dissolution of the lyophilized cake in water results in an aqueous solution with an isotonic osmolality. In certain embodiments, dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 240 to about 340 mOsm/kg.
• dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 280 to about 320 mOsm/kg. In certain embodiments, dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 285 mOsm/kg. In certain embodiments, dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 300 mOsm/kg.
• the composition is an aqueous solution.
• the aqueous solution comprises about 0.03 mg/mL of the polypeptide to about 0.2 mg/mL of the polypeptide.
• the composition comprises about 0.5 mg/mL to about 30 mg/mL of the polypeptide.
• the composition comprises about 1 mg/mL of the polypeptide. [023] In certain embodiments, the composition comprises about 5 mg/mL of the polypeptide.
• the composition comprises about 15 mg/mL of the polypeptide.
• the composition comprises about 20 mg/mL of the polypeptide.
• the composition comprises about 30 mg/mL of the polypeptide. [026] In certain embodiments, the composition comprises about 25 mg/mL to about 35 mg/mL sucrose. In certain embodiments, the composition comprises about 30 mg/mL sucrose.
• the composition comprises about 10 mM to about 20 mM citrate buffer. In certain embodiments, the composition comprises about 12 mM citrate buffer. In certain embodiments, the citrate buffer is formed by the combination of 2.03 mg/mL sodium citrate tribasic dihydrate and 0.97 mg/mL citric acid monohydrate in the aqueous solution. In certain embodiments, the citrate buffer is formed by the combination of 2.91 mg/mL sodium citrate tribasic dihydrate and 0.34 mg/mL citric acid monohydrate in the aqueous solution. In certain embodiments, the citrate buffer is formed by the combination of 2.96 mg/mL sodium citrate tribasic dihydrate and 0.30 mg/mL citric acid monohydrate in the aqueous solution.
• the composition comprises about 0.09 mg/mL to about 0.11 mg/mL polysorbate 20. In certain embodiments, the composition comprises about 0.1 mg/mL polysorbate 20.
• the pH of the composition is about 5.5 to about 6.5. In certain embodiments, the pH of the composition is about 6.1.
• the osmolality of the composition is about 240 to about 340 mOsm/kg. In certain embodiments, the osmolality of the composition is about 280 to about 320 mOsm/kg. In certain embodiments, the osmolality of the composition is about 285 mOsm/kg. In certain embodiments, the osmolality of the composition is about 300 mOsm/kg.
• the composition is a single unit dose of the polypeptide.
• the disclosure provides an aqueous composition comprising: a) about 1 mg/mL to about 30 mg/mL of a polypeptide comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Ra chain; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL mannitol; d) about 10 mM to about 20 mM citrate buffer; and e) about 0.09 mg/mL to about 0.11 mg/mL polysorbate 20, wherein the pH of the solution is about 5.5 to about 6.5.
• the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1. In certain embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.
• the disclosure provides an aqueous composition
• aqueous composition comprising: a) about 1 mg/mL to about 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL mannitol; d) about 10 mM to about 20 mM citrate buffer; and e) about 0.09 mg/mL to about 0.11 mg/mL polysorbate 20, wherein the pH of the solution is about 5.5 to about 6.5.
• the composition comprises about 30 mg/mL sucrose. [037] In certain embodiments, the composition comprises about 30 mg/mL mannitol. [038] In certain embodiments, the composition comprises about 12 mM citrate buffer. [039] In certain embodiments, the composition comprises about 0.11 mg/mL polysorbate 20
• the pH of the solution is about 6.1.
• the composition comprises about 1 mg/mL of the polypeptide. In certain embodiments, the composition comprises about 5 mg/mL of the polypeptide. In certain embodiments, the composition comprises about 15 mg/mL of the polypeptide. In certain embodiments, the composition comprises about 20 mg/mL of the polypeptide. In certain embodiments, the composition comprises about 30 mg/mL of the polypeptide.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 8 mM citrate buffer to about 14 mM citrate buffer (e.g., 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, or 14 mM); and e) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 12 mM citrate buffer; and e) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 2 mg/mL sodium citrate tribasic dihydrate; e) about 1 mg/mL citric acid monohydrate; and f) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 2.03 mg/mL sodium citrate tribasic dihydrate; e) about 0.97 mg/mL citric acid monohydrate; and f) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 3 mg/mL sodium citrate tribasic dihydrate; e) about 0.3 mg/mL citric acid monohydrate; and f) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• an aqueous composition comprising: a) about 1, 5, 15, or 30 mg/mL of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; b) about 25 mg/mL to about 35 mg/mL sucrose; c) about 25 mg/mL to about 35 mg/mL sucrose; d) about 2.91 mg/mL sodium citrate tribasic dihydrate; e) about 0.34 mg/mL citric acid monohydrate; and f) about O.lmg/mL polysorbate 20, wherein the pH of the composition is about 6.1.
• the disclosure provides an article of manufacture comprising any of the foregoing compositions.
• the article is a glass vial.
• the disclosure provides a lyophibzed composition made by lyophibzing any of the foregoing aqueous solutions.
• the disclosure provides a method of making a lyophilized composition, the method comprising lyophibzing any of the foregoing aqueous solutions.
• the disclosure provides a method of making an aqueous composition, the method comprising dissolving any of the foregoing lyophilized compositions in an aqueous solvent.
• the aqueous solvent is water for injection.
• the aqueous solvent is a sodium chloride solution.
• the pH of the aqueous composition is adjusted to about 6.1. In certain embodiments, the pH of the aqueous composition is adjusted to about 6.1 with a base.
• the base is sodium hydroxide.
• the aqueous composition is further diluted with an aqueous solution comprising about 1% (w/w) of a surfactant.
• the surfactant is polysorbate 20.
• the aqueous solution further comprises about 0.1% (w/w) citric acid monohydrate, 0.2% (w/w) sodium citrate tribasic dihydrate, and 98.7% (w/w) water for injection.
• the composition comprises a pharmaceutical composition.
• the disclosure provides a method of activating natural killer cells (NK) cells in a subject, the method comprising administering to the subject an effective amount of any of the foregoing compositions.
• NK natural killer cells
• the disclosure provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the foregoing compositions.
• the cancer is renal cell carcinoma, melanoma, ovarian cancer, or lung cancer.
• the cancer comprises a refractory solid tumor.
• compositions comprising polypeptides comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Ra chain, and methods of making and using such compositions.
• the formulations disclosed herein provide improved stability and shelf-life of the polypeptides contained therein.
• the polypeptide product retains biological activity, including after being lyophilized in the recited formulations and reconstituted in water for injection (WFI) or a similarly acceptable diluent.
• WFI water for injection
• the formulations described herein have been designed to allow the lyophilized product to be reconstituted in WFI, with is readily available to a patient or healthcare provider.
• WFI water for injection
• the formulations described herein possess a physiologically-acceptable osmolality, allowing the reconstituted product to be administered subcutaneously. This eliminates the need for a specialized diluent to reconstitute the lyophilized product with an appropriate osmolality, making it easier for a patient or healthcare provider to use the drug and, therefore, improve drug use compliance.
• Subcutaneous administration has advantages for drug delivery as well.
• the drug When delivered via the subcutaneous route, the drug may be delivered more quickly compared to other delivery routes (e.g., intravenous).
• Subcutaneous delivery may also be performed by a patient in their home, rather than by a healthcare provider in a healthcare facility. This patient-directed delivery may also improve drug use compliance.
• the formulations provided herein also yield a lyophilized cake that has a preferred appearance. Specifically, the cake is intact (not fragmented), has little to no shrinkage from the container (e.g., a glass vial), and have an even, concave surface.
• Circular permutation and “circularly permuted” refer to the process of taking a linear protein, or its cognate nucleic acid sequence, and fusing the native N- and C-termini (directly or through a linker, using protein or recombinant DNA methodologies) to form a circular molecule, and then cutting (opening) the circular molecule at a different location to form a new linear protein, or cognate nucleic acid molecule, with termini different from the termini in the original molecule. Circular permutation thus preserves the sequence, structure, and function of a protein, while generating new C- and N-termini at different locations that results in an improved orientation for fusing a desired polypeptide fusion partner as compared to the original molecule.
• the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of up to ⁇ 5%, including ⁇ 5%, ⁇ 1%, and ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
• the terms “treat,” “treated,” “treating,” or “treatment” include the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated.
• the term “effective amount” in the context of the administration of a therapy to a subject refers to the amount of a therapy that achieves a desired prophylactic or therapeutic effect.
• the term “patient,” “individual” or “subject” refers to a human or a non-human mammal.
• Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals.
• the subject is a human.
• the instant disclosure provides compositions of polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Ra chain.
• the polypeptides employed in the compositions disclosed herein exhibit preferential binding to the intermediate-affinity IL-2R complex comprising IL-2R and the common gamma chain, IL-2Ry) relative to the high-affinity IL-2R complex (comprising IL-2Ra, IL-2R , and IL-2Ry), and behave as selective agonists of the intermediate-affinity IL-2R complex.
• the design and generation of such polypeptides is described in U.S. Patent No. 9,359,415, which is hereby incorporated by reference in its entirety.
• the amino acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID.
• the amino acid sequence of the polypeptide consists of the amino acid sequence of SEQ ID. NO: 1.
• the amino acid sequence of the polypeptide comprises or consists of an amino acid sequence having at least 80 % (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 %) identity to the amino acid sequence of SEQ ID. NO:l.
• the amino acid sequence of the polypeptide comprises or consists of an amino acid sequence having at least 95 % identity to the amino acid sequence of SEQ ID. NO: 1.
• amino acid sequence of the polypeptides employed in the compositions disclosed herein can be derivatized or modified, e.g., pegylated, ami dated, etc.
• the amount of the polypeptide in a formulation is about 1 mg to about 50 mg (e.g., about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 44 mg, about 45 mg, or about 50 mg).
• the amount of the polypeptide is about 1 mg to about 30 mg. In certain embodiments, the amount of the polypeptide is about 1 mg to about 15 mg.
• the amount of the polypeptide is about 1 mg. In certain embodiments, the amount of the polypeptide is about 2.2 mg. In certain embodiments, the amount of the polypeptide is about 5 mg. In certain embodiments, the amount of the polypeptide is about 11 mg. In certain embodiments, the amount of the polypeptide is about 15 mg. In certain embodiments, the amount of the polypeptide is about 20 mg. In certain embodiments, the amount of the polypeptide is about 30 mg. In certain embodiments, the amount of the polypeptide is about 44 mg.
• the concentration of the polypeptide in an aqueous formulation is about 0.5 mg/mL to about 50 mg/mL. In certain embodiments, the concentration of the polypeptide is about 0.5 mg/mL to about 20 mg/mL (e.g., about 0.5 mg/mL, about 1 mg/mL, about 2mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 11 mg/mL, about 12 mg/mL, about 13 mg/mL, about 14 mg/mL, about 15 mg/mL, about 16 mg/mL, about 17 mg/mL, about 18 mg/mL, about 19 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, about 45 mg/mL
• the concentration of the polypeptide is about 1 mg/mL. In certain embodiments, the concentration of the polypeptide is about 5 mg/mL. In certain embodiments, the concentration of the polypeptide is about 15 mg/mL. In certain embodiments, the concentration of the polypeptide is about 20 mg/mL. In certain embodiments, the concentration of the polypeptide is about 30 mg/mL.
• compositions disclosed herein comprise one or more excipients and/or buffers.
• excipient refers to any non-therapeutic agent added to the composition or formulation to provide a desired consistency, viscosity, or stabilizing effect. Suitable excipients for use in the compositions disclosed herein can act, e.g., as viscosity enhancing agents, stabilizers, solubilizing agents, etc.
• the excipient can be ionic or non-ionic. Suitable ionic excipients include salts such as NaCl or amino acid components such as arginine-HCl.
• Suitable non-ionic excipients include sugars, for example, monosaccharides (e.g., fructose, maltose, galactose, glucose, D-mannose, sorbose, etc.); disaccharides (e.g., lactose, sucrose, trehalose, cellobiose, etc.); polysaccharides (e.g., raffmose, melezitose, maltodextrins, dextrans, starches, etc.); and sugar alcohols (e.g., mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), etc.).
• monosaccharides e.g., fructose, maltose, galactose, glucose, D-mannose, sorbose, etc.
• disaccharides e.g., lactose, sucrose, tre
• the sugar may be sucrose, trehalose, raffmose, maltose, sorbitol or mannitol. Additionally or alternatively, the sugar may be a sugar alcohol or an amino sugar. In certain embodiments, the sugar is sucrose and mannitol.
• the amount of the excipient (e.g., sucrose and mannitol) in a formulation is about 1 mg to about 150 mg (e.g., about 1 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, or about 150 mg). In certain embodiments, the amount of the excipient (e.g., sucrose and mannitol) in a formulation is about 30 mg to about 90 mg.
• the amount of the excipient (e.g., sucrose and mannitol) in a formulation is about 60 mg to about 72 mg. In certain embodiments, the amount of the excipient (e.g., sucrose and mannitol) in a formulation is about 66 mg.
• the concentration of the excipient (e.g., sucrose and mannitol) in an aqueous formulation is about 1 mg/mL to about 100 mg/mL (e.g., about 1 mg/mL, about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 45 mg/mL, about 50 mg/mL, about 55 mg/mL, about 60 mg/mL, about 70 mg/mL, about 80 mg/mL, about 90 mg/mL, or about 100 mg/mL).
• the concentration of excipient (e.g., sucrose and mannitol) is about 10 mg/mL to about 50 mg/mL.
• the concentration of excipient is about 25 mg/mL to about 35 mg/mL. In certain embodiments, the concentration of the excipient (e.g., sucrose and mannitol) is about 30 mg/mL.
• Suitable buffering agents for use in the compositions disclosed herein include organic acid and salts, such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid or phthalic acid; Tris, tromethamine hydrochloride, or phosphate buffer.
• amino acid components can also be used as buffering agents. Such amino acid component includes glycine, histidine, and methionine.
• the buffer is a citrate buffer.
• citrate buffer refers to a pH buffering system (in aqueous or lyophilized form) that utilizes citrate ions.
• Citrate buffer can be made using any art recognized methods, including, by combining: (i) citric acid, trisodium citrate dihydrate, and citric acid monohydrate; or (ii) citric acid monohydrate, sodium phosphate dibasic, and citric acid. In certain embodiments, citrate buffer is made using sodium citrate dihydrate and citric acid.
• the amount of the buffering agent (e.g., citrate) in the formulation is about lmg to about 10 mg (e.g., about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg).
• the amount of the buffering agent (e.g., sodium citrate) is about 5.9 mg to about 7.2 mg (e.g., about 5.9 mg, about 6.0 mg, about 6.1 mg, about 6.2 mg, about 6.3 mg, about 6.4 mg, about 6.5 mg, about 6.6 mg about, 6.7 mg about 6.8 mg, about 6.9 mg, about 7.0 mg, about 7.1 mg, or about 7.2 mg).
• the amount of the buffering agent e.g., citrate
• the amount of the citrate anion in the buffering agent is about 4.0 mg to about 6.0 mg.
• the amount of the citrate anion in the buffering agent is about 5.0 mg.
• the concentration of the buffering agent (e.g., citrate) in an aqueous formulation disclosed herein is about 1 mM to about 50 mM (e.g., about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, or about 50 mM).
• the buffering agent e.g., citrate
• the concentration of the buffering agent is about 11 mM to about 13 mM (e.g., about 11.1 mM, 11.2 mM, 11.3 mM, 11.4 mM, 11.5 mM, 11.6 mM, 11.7 mM, 11.8 mM, 11.9 mM, 12.1 mM, 12.2 mM, 12.3 mM,
• the concentration of the buffering agent is about 12 mM. In certain embodiments, the concentration of the buffering agent (e.g., citrate) is about 11.95 mM. In certain embodiments, the concentration of the buffering agent (e.g., citrate) is about 11.67 mM.
• the citrate buffer contains 2.03 mg/mL (6.90 mM) sodium citrate tribasic dihydrate and 0.97 mg/mL (5.05 mM) citric acid. In certain embodiments, the citrate buffer contains 2.91 mg/mL (9.90 mM) sodium citrate tribasic dihydrate and 0.34 mg/mL (1.77 mM) citric acid.
• compositions disclosed herein have a pH of about 5.0 to about 8.0, of about 5.5 to about 7.5, of about 5.0 to about 7.0, of about 6.0 to about 8.0, or of about 6.0 to about 7.0. In certain embodiments, the compositions have a pH of about
• the compositions have a pH of about 5.8 to about 6.4. In certain embodiments, the compositions have a pH of about 6.1. In certain embodiments, the pH of the composition is adjusted to a pH of about 6.1. In certain embodiment, the pH is adjusted with a base. In certain embodiments, the base is a hydroxide salt, such as sodium hydroxide (NaOH) or potassium hydroxide (KOH). In certain embodiments, the composition is an aqueous composition and the pH of the aqueous composition is adjusted to a pH of about 6.1.
• the compositions disclosed herein have an isotonic osmolality.
• osmolality of the composition is about 240 to about 340 mOsm/kg.
• osmolality of the composition is about 280 to about 320 mOsm/kg.
• the osmolality of the composition is about 285 mOsm/kg.
• the osmolality of the composition is about 300 mOsm/kg.
• surfactant refers to organic substances having amphipathic structures; i.e., they are composed of groups of opposing solubility tendencies, typically an oil-soluble hydrocarbon chain and a water-soluble ionic group. Surfactants can be classified, depending on the charge of the surface-active moiety, into anionic, cationic and dispersing agents for various pharmaceutical compositions and preparations of biological materials. Suitable surfactants for use in the compositions disclosed herein include non-ionic surfactants, ionic surfactants and zwitterionic surfactants.
• Typical surfactants for use with the invention include sorbitan fatty acid esters (e.g., sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate), sorbitan trioleate, glycerine fatty acid esters (e.g., glycerine monocaprylate, glycerine monomyristate, glycerine monostearate), polyglycerine fatty acid esters (e.g., decaglyceryl monostearate, decaglyceryl distearate, decaglyceryl monolinoleate), polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan tristearate), polyoxyethylene sorbitol
• compositions may include one or more of these surfactants.
• the compositions disclosed herein comprise polyoxyethylene sorbitan fatty acid esters e.g., polysorbate 20, 40, 60 or 80. In certain embodiments, the compositions disclosed herein comprise polysorbate 20.
• the amount of the surfactant (e.g., polysorbate 20) in the formulation is about 0.1 mg to about 1 mg (e.g., about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.35 mg, about 0.4 mg, about 0.45 mg, about 0.5 mg, about 0.55 mg, about 0.6 mg, about 0.65 mg, about 0.7 mg, about 0.75 mg, about 0.8 mg, about 0.85 mg, about 0.9 mg, about 0.95 mg, or about 1 mg).
• the amount of the surfactant (e.g., polysorbate 20) is about 0.15 mg to about 0.3 mg (e.g., about 0.16 mg, about 0.17 mg, about 0.18 mg, about 0.19 mg, about 0.21 mg, about 0.22 mg, about 0.23 mg, about 0.24 mg, about 0.26 mg, about 0.27 mg, about 0.28 mg, or about 0.29 mg).
• the amount of the surfactant (e.g., polysorbate 20) is about 0.20 mg to about 0.24 mg.
• the amount of the surfactant (e.g., polysorbate 20) in an aqueous formulation is about 0.22 mg.
• the composition comprises about 0.10 mg to about 0.12 mg polysorbate 20. In certain embodiments, the composition comprises about 0.11 mg polysorbate 20.
• the concentration of the surfactant (e.g., polysorbate 20) in an aqueous formulation is about 0.01 mg/mL to about 1 mg/mL (e.g., about 0.01 mg/mL, about 0.1 mg/mL, about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, about 0.6 mg/mL, about 0.7 mg/mL, about 0.8 mg/mL, about 0.9 mg/mL, or about 1 mg/mL).
• the concentration of the surfactant is about 0.05 mg/mL to about 0.15 mg/mL (e.g., about 0.05 mg/mL, about 0.06 mg/mL, about 0.07 mg/mL, or about 0.08 mg/mL about 0.09 mg/mL, about 0.1 mg/mL, about 0.11 mg/mL, about 0.12 mg/mL, about 0.13 mg/mL, about 0.14 mg/mL, or about 0.15 mg/mL,).
• the concentration of the surfactant (e.g., polysorbate 20) is about 0.09 mg/mL to about 0.11 mg/mL.
• the concentration of the surfactant (e.g., polysorbate 20) in an aqueous formulation is about 0.1 mg/mL.
• compositions and compositions of the present invention may be described by units other than mg/mL.
• the components of the compositions and compositions of the present invention may be described in units of molarity.
• the components of the compositions and compositions of the present invention may be further described in units of weight or mass percent.
• the instant disclosure provided lyophilized compositions (e.g., lyophilized cake) of the polypeptides disclosed herein, and methods of making the same.
• j Lyophilization generally includes three main stages: freezing, primary drying and secondary drying. Freezing is necessary to convert water to ice or some amorphous formulation components to the crystalline form. Primary drying is the process step when ice is removed from the frozen product by direct sublimation at low pressure and temperature. Secondary drying is the process step when bounded water is removed from the product matrix utilizing the diffusion of residual water to the evaporation surface. Product temperature during secondary drying is normally higher than during primary drying. See, Tang X. et al.
• compositions disclosed herein contain a particular combination of constituents allow for stable long-term storage of the polypeptides disclosed herein that comprise a circularly permuted interleukin-2 (IL- 2) fused to the extracellular portion of an IL-2Ra chain.
• IL- 2 circularly permuted interleukin-2
• the disclosure provides a lyophilized composition made by lyophilizing any one of the aqueous compositions disclosed herein that comprise a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Ra chain.
• the lyophilized composition is a lyophilized cake.
• the lyophilized composition is made by lyophilizing any one of the aqueous compositions disclosed herein following the lyophilization protocol recited in Table 11 A or Table 1 IB.
• the disclosure provides a method of making a lyophilized composition, the method comprising lyophilizing any one of the aqueous compositions disclosed herein that comprise a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Ra chain.
• the method of making a lyophilized composition comprises following the lyophilization protocol recited in Table 11 A or Table 11B.
• the disclosure provides a method of making an aqueous composition, the method comprising dissolving in an aqueous solvent any one of the lyophilized compositions disclosed herein that comprise a circularly permuted interleukin- 2 (IL-2) fused to the extracellular portion of an IL-2Ra chain.
• the lyophilized composition is a lyophilized cake.
• the lyophilized composition is dissolved in 1.1 ml of water.
• the lyophilized composition is dissolved in 2.2 ml of water.
• compositions disclosed herein are particularly useful for the treatment, prevention, or amelioration of any disease or disorder associated with Interleukin 2 receptor signaling.
• NK natural killer cells
• a method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of any one of the compositions disclosed herein that comprise a circularly permuted IL-2 fused to the extracellular portion of an IL-2Ra chain.
• Cancers suitable for treatment using the composition disclosed herein include renal cell carcinoma, melanoma, ovarian cancer, and lung cancer.
• the cancer comprises a refractory solid tumor.
• the composition is administered subcutaneously. [098] In certain embodiments, the composition is administered subcutaneously at a dose of about 1 mg to about 15 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 1 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 2 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 3 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 4 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 5 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 6 mg.
• the composition is administered subcutaneously at a dose of about 7 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 8 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 9 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 10 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 11 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 12 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 13 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 14 mg. In certain embodiments, the composition is administered subcutaneously at a dose of about 15 mg.
• the composition is administered subcutaneously once a week (Q1W), once every two weeks (Q2W), or once every three weeks (Q3W).
• the composition is administered subcutaneously at a dose of about 1 mg to about 15 mg once a week (Q1W), once every two weeks (Q2W), or once every three weeks (Q3W).
• the composition is administered subcutaneously at a dose of about 3 mg once a week (Q1W). In certain embodiments, the composition is administered subcutaneously at a dose of about 6 mg once every three weeks (Q3W).
• the melanoma is one or both of mucosal melanoma or advanced cutaneous melanoma.
• a formulation that results in a non-isotonic solution when reconstituted with WFI would not be amenable to subcutaneous administration.
• the second objective was to produce a lyophilized cake with optimal cake appearance that has minimal cake shrinkage. An improved cake appearance may make the drug product more visually appealing to a patient or healthcare provider, thus potentially improving compliance in drug use.
• Table 1 below recites the specific components and their concentrations for the Polypeptide A formulation that was initially designed for intravenous administration.
• FTIR analysis was performed using PROTA FTIR Protein Analyzer equipped with a CaF2 Biocell and ATR cell for solid sample analysis. Approximately 10 pL of liquid sample or 10 mg of lyophilized powder sample was loaded for the analysis. Absorbance signals were processed by subtracting interfering signals from background lyophilized placebo and buffer where appropriate. The processed data were finally converted to second derivative signals to improve the resolution with parameters set as 100 scans with a 4 cm 1 resolution. To identify the percentage of the different structural elements of the Polypeptide A native protein, the subtracted spectrum was processed through the protein secondary structure database. The percent similarity between the native state and the dried state was calculated based on the area of overlap from 1700 to 1600 cm 1 or 1800 to 1400 cm 1 .
• DSC analysis was performed using TA Q20 with a refrigerated cooling system I.
• TA Q20 For sub-ambient (frozen state) DSC, approximately 15 pL of the formulated drug substance was loaded into DSC pan and hermetically sealed. The sample was then cooled to -90°C at 10°C/minute. The pans were held in the sample chamber for 2 minutes prior to warming to 30°C at 10°C/minute. During annealing, the sample was warmed to -10°C after holding at -90°C for 2 minutes, then cooled back to -90°C prior to warming to 30°C at 10°C/minute.
• the first screening involved various formulations to understand how different combinations of stabilizers, bulking agents, etc. would impact the glass transition or collapse temperature (Tg’) and the isotonicity. All formulations contained 12 mM sodium citrate buffer at pH 6.11 as the base formulation prior to the addition of the screening excipients. Tween 21 was used as a surface stabilizer. The formulations evaluated in this study with sub-ambient DSC and osmolality analyses are summarized in Table 2.
• glycine formulations were prepared to replace Formulations 1 and 2 to target osmolality of 290 mOsm/kg, with a corresponding glass transition temperature of - 28.23°C by DSC. Additionally, concentrations of sucrose and mannitol excipients in Formulations 3 and 4 were adjusted to increase the osmolality values. Four new formulations were lyophilized and analyzed in screening study 2.
• Table 6 depicts 5 formulations that were prepared as described above for screening study 3 and freeze-dried using lyophilization cycle parameters described in Table 4. No osmolality measurements were performed. Tween 20 (PS20) was used in this study at 0.1 mg/mL for Formulations 17-21.
• FTIR spectra were measured as described above to determine the percent similarity to native Polypeptide A. Based on the above results, a higher amount of disaccharide was confirmed to have a higher impact on the retention of secondary structure. The next screening study was designed to investigate higher concentrations of disaccharides in combination with bulking agents.
• Table 8 depicts 5 formulations that were prepared as described above for screening study 3.
• Tween 20 PS20
• PS20 was used in this study at 0.1 mg/mL for Formulations 31-35.
• Glycine in Formulations 33 and 34 interfered with the FTIR analysis, hence there is no percent similarity data reported.
• generating an effective lyophilization cycle with glycine was more difficult than mannitol. Therefore, mannitol-containing formulations were pursued further.
• Formulations 31 and 32 were tested for appearance, glass transition temperature in the frozen state (Tg’), and glass transition temperature in the dried state (Tg).
• the intravenous administration formulation for Polypeptide A was used as a comparator. Compositions of the three formulations evaluated in this screen are described in Table 10.
• the vials contained white intact cakes.
• the formulation containing 50 mg/mL sucrose (Formulation 36) displayed slight cake shrinkage. All other formulations were fully intact with no signs of shrinkage.
• Table 12 summarizes the results after high temperature DSC analysis.
• Glass transition temperature (Tg) values for Formulation 36 and 37 were determined at ⁇ 82 °C, attributed to sucrose.
• the glass transition of the formulation containing trehalose (Formulation 38) could not be detected under these conditions.
• the melting peak detected for Formulation 36 at 158 °C was attributed to the melting of sucrose.
• the melting peaks detected for Formulation 37 and 38 at 120-121 °C were attributed to the melting of mannitol.
• Table 12 Summary of Tg and Melting Temperature pH. Reconstitution Time Osmolality Concentration and Moisture Content for Leading Formulation Candidates
• SE-HPLC and RP-HPLC analysis of Formulations 36, 37, and 38 was performed.
• the integrated results for the SE-HPLC analysis showed the largest peak having a peak area of >98% for each formulation.
• the integrated results for the RP-HPLC analysis showed the largest peak having a peak area of >85% for each formulation.
• Formulations 36-38 were compared using a pSTAT5 Activity Assay.
• the dose response curves were similar and comparable to that of a Polypeptide A Reference Standard.
• Data analysis in Table 14 showed EC50 values that were greater than 75% potency relative to the Reference Standard RT, which is acceptable.
• the pSTAT5 activity assay was performed by measuring binding of the formulations to HH cells (a human T lymphocyte cell line which have the bgIT2 receptor isoform present on their surface). Polypeptide A binding was measured by determining the amount of phosphorylated STAT5 (phospho-STAT5 or pSTAT5) present in the HH cells after contact with each formulation, using an ELISA assay.
• the Invitrogen InstantOne ELISA phosphor-STAT5 alpha/beta (pTyr694/pTyr699) kit was used to perform the ELISA assay.
• the drug product sample was prepared by reconstituting the sample in 2.2 mL WFI. The sample was visually inspected to ensure that contents were free of visible particulates.
• a sample diluent was prepared by adding 25 mL of Fetal Bovine Serum (FBS) to 500 mL of Hanks Balanced Salt Solution (HBSS) for a final concentration of 5% FBS and warmed to 37°C.
• a wash buffer comprising Phosphate Buffered Saline (PBS) with 0.05% Tween 20 was used.
• Samples and standards were diluted to final protein concentrations in the assay of 750 ng/mL, 250 ng/mL, 83 ng/mL, 28 ng/mL, 9.3 ng/mL, 3.1 ng/mL, 1.0 ng/mL, and 0.3 ng/mL.
• a stock solution of HH cells at a density of approximately 1.2 x 10 6 cells/mL was prepared and 50 pi of the cell stock solution was added to each well of a 96-well plate that contained the diluted sample or standard.
• the cells were incubated at 37 °C for 30 minutes. After incubation, the cells were lysed in a cell lysis buffer for 10 minutes. After lysis, 50 m ⁇ of the lysed cell mix was transferred to an ELISA plate followed by 50 m ⁇ of phospho-STAT5 A/B antibody cocktail. The mix was then incubated for 1 hour then washed 3 times with wash buffer. 100 m ⁇ of a detection reagent was then added to each well and the plate was incubated for 15 minutes. 100 m ⁇ of a stop solution was then added to each well and the plate was read at 450 nm on a microplate reader.
• sucrose and mannitol were altered from Formulation 37 as shown in Table 17 to test osmolality and monitor lyophilized cake appearance.
• Each formulation below in Table 17 had a sodium citrate buffer at 12 mM and a pH of 6.1.
• Formulation 37 had the best lyophilized cake appearance, showing more of a concave top appearance and no shrinkage on the walls compared to the other formulations.
• the improved cake appearance may make the drug product more visually appealing to a patient or healthcare provider, thus potentially improving compliance in drug use.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Immunology (AREA)
• Toxicology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cell Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Dermatology (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=78524880

Family Applications (1)

Country Status (12)

Citations (3)

Family Cites Families (3)

• 2021
  • 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
  • 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
  • 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Pending
  • 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
  • 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en not_active Abandoned
  • 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
  • 2021-05-10 US US17/315,974 patent/US20210395325A1/en not_active Abandoned
  • 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
  • 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
  • 2021-05-10 IL IL298064A patent/IL298064A/en unknown
  • 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en not_active Ceased
  • 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events